Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Meditory : The Journal of Medical Laboratory
Ni Wayan Armerinayanti
Faculty of Medicine Warmadewa University
Biochemistry, Genetics & Molecular Biology Environmental Science

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
HIGH MATRIX METALLOPROTEINASE 9 EXPRESSION AS A RISK FACTOR OF LYMPHOVASCULAR INVASION IN CERVICAL CARCINOMA Ni Wayan Armerinayanti
Meditory : The Journal of Medical Laboratory Vol. 13 No. 2 (2025): Meditory, Volume 13 No. 2 Tahun 2025
Publisher : Jurusan Teknologi Laboratorium Medis, Poltekkes Kemenkes Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33992/meditory.v13i2.4204

Abstract

Background: Cervical carcinoma is an epithelial cancer with the highest mortality among female genital malignancies. Its poor prognosis is largely related to metastasis, which begins early through lymphovascular space invasion (LVSI). LVSI occurs when cancer cells invade surrounding tissue via proteolytic enzymes, but early prediction remains difficult. Although several molecular markers have been studied, none is definitive, and the role of matrix metalloproteinase-9 (MMP-9) in LVSI remains controversial.Objective: This study will prove MMP-9 as a risk factor for LVSI in cervical carcinomaMethods: This case–control study analyzed 40 archived paraffin-embedded tissue blocks from cervical carcinoma patients at BaliMed Denpasar Hospital. Immunohistochemical staining was performed to assess MMP-9 expression, while hematoxylin and eosin (H&E) staining was used to evaluate lymphovascular space invasion (LVSI). Statistical analysis was conducted using the chi-square test in SPSS version 25.Results: The study showed that 85,7% of cervical carcinomas with LVSI have high MMP-9 expression, with a significant result compared to cervical cancer without LVSI (p=0.001, OR= 13.5).Conclusions: The MMP-9 expression was significantly associated with the risk of LVSI in cervical carcinoma 
EFFICACY AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELL (CAR-T) THERAPY IN LYMPHOMA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS I Gede Krisna Arim Sadeva; I Gede Wikania Wira Wiguna; Ni Wayan Armerinayanti; Putu Mirah Wahyu Subagia Putri; Christo Timothy Mamangdean; Putu Ari Shanti Dewi; Kadek Meryndha Kumala Tungga; I Komang Raditya Putra Pratama; Agung Brahmanthya Nadine Kepakisan; Komang Indra Parama  Arta
Meditory : The Journal of Medical Laboratory Vol. 14 No. 1 (2026): Meditory, Volume 14 No. 1 Tahun 2026
Publisher : Jurusan Teknologi Laboratorium Medis, Poltekkes Kemenkes Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33992/meditory.v14i1.5125

Abstract

Abstract Background: Lymphoma (Hodgkin and non-Hodgkin) is a malignancy of the lymphatic system, with global prevalence reaching 2.8% and mortality rates reaching 248,700 cases each year. Therefore, Chimeric Antigen Receptor-Modified T cell therapy (CAR-T) was developed as a new approach to improve survival rates in lymphoma patients. Objective: This study aimed to evaluate the efficacy and safety of CAR-T cell therapy in lymphoma. Methods: PRISMA 2020 was used in the literature search and systematic review with the keywords "CAR-T Cell Therapy" and "Lymphoma". All statistical analyses were performed with R statistical software version 3.3 and MedCalc software version 22. A p-value ≤ 0.05 was considered statistically significant. Results: There were 16 studies involving 440 patients with lymphoma. The complete response rate was 62% (95% CI 55%-65%, I² = 40%). Meanwhile, cytokine release syndrome (CRS) occurred in 73% of cases (95% CI 49%-88%, I² = 80%). The overall Immune effector cell-associated neurotoxicity syndrome (ICANS) rate was 17% (95% CI 9%-30%, I² = 66%). There is no significant publication bias in all analyses (p-value>0.05). However, these results need to be interpreted with caution, considering the high heterogeneity in the pooled analysis results (I² > 50%).
Co-Authors Agung Brahmanthya Nadine Kepakisan Christo Timothy Mamangdean I Gede Krisna Arim Sadeva I Gede Wikania Wira Wiguna I Komang Raditya Putra Pratama Kadek Meryndha Kumala Tungga Komang Indra Parama  Arta Putu Ari Shanti Dewi Putu Mirah Wahyu Subagia Putri